Comparable endemic coronavirus nucleoprotein-specific antibodies in mild and severe Covid-19 patients

J Med Virol. 2021 Sep;93(9):5614-5617. doi: 10.1002/jmv.27038. Epub 2021 May 3.

Abstract

The severity of disease of Covid-19 is highly variable, ranging from asymptomatic to critical respiratory disease and death. Potential cross-reactive immune responses between SARS-CoV-2 and endemic coronavirus (eCoV) may hypothetically contribute to this variability. We herein studied if eCoV nucleoprotein (N)-specific antibodies in the sera of patients with mild or severe Covid-19 are associated with Covid-19 severity. There were comparable levels of eCoV N-specific antibodies early and during the first month of infection in Covid-19 patients with mild and severe symptoms, and healthy SARS-CoV-2-negative subjects. These results warrant further studies to investigate the potential role of eCoV-specific antibodies in immunity to SARS-CoV-2 infection.

Keywords: COVID-19; disease severity; endemic coronaviruses; nucleoprotein-specific antibodies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Viral / blood
  • Antibodies, Viral / immunology*
  • COVID-19 / blood
  • COVID-19 / immunology*
  • COVID-19 Serological Testing
  • Cross Reactions
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nucleoproteins / immunology*
  • SARS-CoV-2 / immunology*
  • Severity of Illness Index
  • Sweden
  • Young Adult

Substances

  • Antibodies, Viral
  • Nucleoproteins